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Background: Renal mass biopsy (RMB) has had limited and varied utilization to
guide management of renal masses (RM).
Objective: To evaluate utilization of RMB for newly diagnosed cT1 RMs across
diverse practice types and assess associations of outcomes with RMB.
Design, setting, and participants: MUSIC-KIDNEY commenced data collection in
September 2017 for all newly presenting patients with a cT1 RM at 14 diverse
practices. Patients were assessed at 120 d after initial evaluation.
Outcome measurements and statistical analysis: Demographics and outcomes
were compared for patients undergoing RMB versus no RMB. Clinical and demographic characteristics were summarized by RMB status using a x2 test for categorical variables and Student t test for continuous variables. A mixed-effects logistic
regression model was constructed to identify associations with RMB receipt.
Results and limitations: RMB was performed in 15.5% (n = 282) of 1808 patients
with a cT1 RM. Practice level rates varied from 0% to 100% (p = 0.001), with only ﬁve
of 14 practices using RMB in >20% of patients. On multivariate analysis, predictors
of RMB included greater comorbidity (Charlson comorbidity index 2 vs 0: odds
ratio [OR] 1.44; p = 0.025) and solid lesion type (cystic vs solid: OR 0.17; p = 0.001;
indeterminate vs solid: OR 0.58; p = 0.01). RMB patients were less likely to have
benign pathology at intervention (5.0% vs 13.5%; p = 0.01). No radical nephrectomies were performed for patients with benign histology at RMB. The limitations
include short follow-up and inclusion of practices with low numbers of RMBs.
Conclusions: Utilization of RMB varied widely across practices. Factors associated
with RMB include comorbidities and lesion type. Patients undergoing RMB were
less likely to have benign histology at intervention.
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Patient summary: Current use of biopsy for kidney tumors is low and varies across
our collaborative. Biopsy was performed in patients with greater comorbidity (more
additional medical conditions) and for solid kidney tumors. Pretreatment biopsy is
associated with lower nonmalignant pathology detected at treatment.
© 2021 The Authors. Published by Elsevier B.V. on behalf of European Association of
Urology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1.

Introduction

Increasing detection of small renal masses (SRMs), partly
driven by greater use of abdominal imaging, has resulted in
increases in the rates of detection and intervention for
presumed renal cell carcinoma (RCC). No clinical or
conventional radiographic features are able to accurately
predict histology, so contemporary series of surgical
interventions report a benign final pathology rate of 20–
30% for cT1a tumors [1].
It has been shown that renal mass biopsy (RMB) is safe and
accurate, with low rates of adverse events [2] and reported
sensitivity of 97.5–99.7%, specificity of 96.2–99.1%, and a
positive predictive value of 99.8% in two large meta-analyses
[2,3]. When an RMB-based management approach was
applied to a large partial nephrectomy (PN) data set, it was
felt that almost half of the surgeries were potentially avoidable
[4]. However, adoption of RMB has been limited, with a recent
survey showing that 31.8% of urologists would never consider a
biopsy for a cT1a renal mass [5]. Opponents argue that the
results do not influence management substantially and that
novel imaging modalities can provide as useful information as
RMB via a noninterventional study [6,7].
The Michigan Urological Surgery Improvement Collaborative (MUSIC) established Kidney Mass: Identifying and
Defining Necessary Evaluation and Therapy (MUSIC-KIDNEY) as a quality improvement initiative for patients with a
renal mass 7 cm (cT1 RM). The aim of our study was to
assess the use of RMB for newly diagnosed cT1 RM across a
range of practice types, using data collected through a
statewide quality improvement collaborative.
2.

Patients and methods

The MUSIC-KIDNEY conception and data collection methods have been

2.2.

Patient characteristics and outcomes

For each patient, the following variables were extracted: age, gender,
Charlson comorbidity index (CCI), race (white vs black vs others),
insurance category (private vs public [Medicare, Medicaid] vs uninsured
vs unknown), estimated glomerular ﬁltration rate (eGFR), body mass
index (BMI), tumor size, tumor position (anterior vs posterior), polar
location (upper vs mid vs lower pole), tumor nephrometry score (RENAL
score), tumor characteristics (solid vs cystic), tumor management, and
ﬁnal histology if available. For patients who underwent treatment with
or without RMB, additional information was extracted from the data set,
including biopsy histology, treatment, and surgical pathology, where
available. Patients with biopsy results indicating malignancy or favoring
malignancy were grouped, results with a benign diagnosis or favoring a
benign diagnosis were grouped, and patients undergoing biopsy and
ablation at the same time were assigned to a no-RMB group, as it was
assumed that the biopsy result did not aid in decision-making regarding
treatment. RMB results were classiﬁed as indeterminate if there was
insufﬁcient information to determine the probability of malignant
versus benign histology or no tumor tissue was sampled.

2.3.

Statistical analysis

Patient clinical and demographic characteristics were summarized by
RMB status using a x2 test for categorical variables and Student t test for
continuous variables. Practice-level variation in the utilization of RMB
for cT1 RM patients was examined. A mixed-effects logistic regression
model was constructed to identify factors associated with RMB versus no
RMB. The model included patient-level characteristics as predictors, and
random intercepts for each practice/hospital to account for withinpractice correlation. All the analyses were performed using SAS version
9.4 (SAS Institute, Cary, NC, USA) and statistical signiﬁcance was set at
p = 0.05.

3.

Results

3.1.

Predictors of RMB utilization

previously outlined [8]. The MUSIC coordinating center is responsible for
overall administration and management of collaborative activities. One
urologist per practice serves as the clinical champion, with responsibilities that include oversight of local data collection and leadership around
local implementation of quality improvement activities. Data abstractors
recorded 122 data points at a single time point (120 d after initial
consultation).

2.1.

Study population

Our data set consisted of patients presenting to a urologist for the ﬁrst
time with a renal lesion measuring 7 cm. Exclusion criteria for the
analysis included age <18 yr, documented Bosniak I, II, and IIF cysts, and
imaging-determined angiomyolipoma.

Among 1808 patients with a cT1 RM, 282 (15.5%) underwent
RMB to assist in management. The patient and tumor
characteristics associated with RMB (Table 1) included
increasing comorbidity (p = 0.001), academic practice
(p = 0.001), higher BMI (p = 0.025), posterior tumor location
(p = 0.033), and tumor type (p < 0.001). The rate of RMB
utilization was 17.9% for solid masses, 10.3% for indeterminate lesions, and 3.5% for Bosniak III/IV cysts. The RMB
utilization rate was much lower for the smallest tumors
(1.2% for tumors 1 cm) than for tumors of 1.1–7.0 cm. For
tumors between 1.1 and 7.0 cm, rates were similar (Fig. 1). In
particular, for tumors of 1.1–4.0 cm and 4.1–7.0 cm (T1b) in
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Table 1 – Patient, physician, and tumor characteristics for RMB versus no RMB
Variable

All patients

Patients (n)
Mean age, yr (SD)
Mean BMI, kg/m2 (SD)
Race, n (%)
White
African American
Other
Unknown
Sex, n (%)
Male
Female
Insurance, n (%)
Private
Public
None
Unknown
eGFR, n (%)
>60 ml/min/1.73 m2
60 ml/min/1.73 m2
CCI, n (%)
0
1
2
Multiple lesions, n (%)
No
Yes
Tumor type, n (%)
Solid
Indeterminate
Complex cyst
Tumor size, n (%)
0–1.0 cm
1.1–2.0 cm
2.1–3.0 cm
3.1–4.0 cm
4.1–5.0 cm
5.1–6.0 cm
6.1–7.0 cm
Practice type, n (%)
Academic
Private
Practice location, n (%)
Southeast Michigan
Elsewhere
Tumor location, n (%) a
Anterior
Posterior
Tumor location, n (%) a
Upper, upper/mid
Mid
Lower, lower/mid
RENL, n (%) a
Low
Intermediate
High

RMB

No RMB

1808
64.0 (13.3)
31.2 (8.0)

282
63.7 (13.1)
32.1 (8.1)

1526
64.0 (13.4)
31.0 (8.0)

1389 (76.8)
257 (14.2)
43 (2.4)
119 (6.6)

224 (79.4)
35 (12.4)
7 (2.5)
16 (5.7)

1165 (76.4)
222 (14.5)
36 (2.4)
103 (6.7)

1062 (58.7)
746 (41.3)

175 (62.1)
107 (37.9)

887 (58.1)
639 (41.9)

953 (52.7)
826 (45.7)
27 (1.5)
2 (0.1)

151 (53.5)
130 (46.1)
1 (0.4)
0

802 (52.6)
696 (45.6)
26 (1.7)
2 (0.1)

1111 (70.7)
460 (29.3)

169 (67.6)
81 (32.4)

942 (71.3)
379 (28.7)

942 (52.1)
341 (18.9)
525 (29.0)

121 (42.9)
55 (19.5)
106 (37.6)

821 (53.8)
286 (18.7)
419 (27.5)

1596 (89.0)
198 (11.0)

249 (89.2)
30 (10.8)

1347 (88.9)
168 (11.1)

1355 (74.9)
339 (18.8)
114 (6.3)

243 (86.2)
35 (1.4)
4 (12.4)

1112 (72.9)
304 (7.2)
110 (19.9)

85 (4.7)
508 (28.1)
472 (26.1)
295 (16.3)
211 (11.7)
155 (8.6)
82 (4.5)

1 (0.4)
71 (25.2)
82 (29.1)
56 (19.9)
36 (12.8)
21 (7.4)
15 (5.3)

84 (5.5)
437 (28.6)
390 (25.6)
239 (15.7)
175 (11.5)
134 (8.8)
67 (4.4)

353 (19.5)
1455 (80.5)

82 (23.2)
200 (13.7)

271 (76.8)
1255 (86.3)

1396 (77.2)
412 (22.8)

206 (29.1)
76 (70.9)

1190 (17.8)
336 (82.2)

154 (45.8)
182 (54.2)

16 (32.0)
34 (68.0)

138 (48.3)
148 (51.7)

513 (33.5)
476 (31.1)
543 (35.4)

79 (32.4)
87 (35.7)
78 (31.9)

434 (33.7)
389 (30.2)
465 (36.1)

337 (41.3)
358 (43.9)
120 (14.7)

63 (39.6)
70 (44.0)
26 (16.4)

274 (41.8)
288 (43.9)
94 (14.3)

p value

0.724
0.025
0.684

0.218

0.344

0.237

0.001

0.869

<0.001

0.004

<0.001

0.070

0.033

0.217

0.779

BMI = body mass index; CCI = Charlson comorbidity index; eGFR = estimated glomerular ﬁltration rate; RMB = renal mass biopsy; RENL = radius, exophytic/
endophytic, nearness, and location items from the RENAL score; SD = standard deviation.
a
Analysis performed on available data as indicated in the “All patients” column.

size, there was no difference in the RMB utilization rate
(15.9% vs 16.3%; p = 0.87).
There was substantial variation in utilization across the
14 urology practices evaluated. The median practice-level
utilization of RMB was 11.3% (IQR 2–24%), with a wide range
from 0% to 100% (p = 0.001). Only five of the 14 practices
used RMB in >20% of cT1 RM cases. Provider-level

differences in utilization of RMB were also noted, but the
data are somewhat limited by the small number of
evaluable patients for a provider-by-provider analysis (data
not shown).
In multivariable analysis (Table 2), the factors associated
with RMB utilization were CCI and tumor type. Patients
with CCI of 2 were more likely to undergo RMB (odds ratio
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Fig. 1 – Utilization of renal mass biopsy according to tumor size in 1-cm increments.

[OR] 1.44; p = 0.025) compared to those without comorbidity. Patients with complex cystic (OR 0.17; p = 0.001) and
indeterminate lesions (OR 0.58; p = 0.01) were less likely to
undergo RMB compared to patients with solid tumors.
3.2.

Outcomes according to RMB utilization and biopsy results

The results for RMB before treatment for cT1 RMs include
70.6% with malignant pathology, 20.6% with benign
pathology, and 9.8% with indeterminate results. The
sensitivity and specificity of RMB were 98.1% and 60.0%,
respectively, for the 119 patients undergoing surgical
treatment. Five patients with indeterminate results on
RMB underwent surgical intervention, four with RCC and
one patient with benign histology. Two patients were
classified as having malignant disease at RMB (oncocytic
neoplasm favoring chromophobe RCC) but pathology at

Table 2 – Multivariable logistical regression analysis to identify
factors associated with undergoing RMB versus no RMB
Comparison
Age
Body mass index
African American vs White
Other vs White
Unknown vs White
Female vs male
Public vs private insurance
None/unknown vs private insurance
Academic vs community practice
Southeast Michigan vs elsewhere
in Michigan
Charlson comorbidity index 1 vs 0
Charlson comorbidity index 2 vs 0
Multiple lesions vs single lesion
Bosniak III/IV cyst vs solid lesion
Indeterminate vs solid lesion
T1b vs T1a tumor size

OR (95% CI)

p value

1.00 (0.99–1.01)
1.01 (0.99–1.03)
1.01 (0.67–1.53)
0.85 (0.34–2.10)
1.02 (0.57–1.83)
0.87 (0.66–1.14)
1.08 (0.81–1.45)
0.24 (0.03–1.90)
1.85 (0.79–4.33)
1.17 (0.55–2.47)

0.561
0.196
0.955
0.718
0.953
0.307
0.611
0.176
0.156
0.687

1.25 (0.87–1.80)
1.44 (1.05–1.98)
0.88 (0.57–1.35)
0.17 (0.06–0.46)
0.58 (0.38–0.88)
1.01 (0.75–1.37)

0.233
0.025
0.546
0.001
0.010
0.933

CI = conﬁdence interval; OR = odds ratio; RMB = renal mass biopsy.

surgery revealed benign (oncocytoma) findings. The four
patients with benign RMB histology who underwent
surgery all had confirmation of oncocytoma on final surgical
pathology.
The proportion of patients receiving the three main
treatment choices (observation, nephron-sparing intervention, or radical nephrectomy [RN]) did not significantly
differ between the RMB and no-RMB groups (p = 0.13).
However, in the cohort undergoing RMB, treatment choice
was dramatically different (Fig. 2). If a benign histology
outcome was obtained at RMB, patients were far more likely
to undergo observation than with a malignant RMB result
(94.7% vs 30.2%; p < 0.001). Of note, no patients with a
benign RMB result underwent RN. A total of 64 patients
underwent ablation during the study time period. Twentyeight of these patients had a biopsy with suspicion of
malignancy before ablation. It is possible that the RMB
results may have influenced management by either helping
to justify treatment decisions or changing treatment
decisions after RMB.
The rate of nonmalignant pathology (NMP) at surgical
intervention was 5.0% with RMB and 13.4% without RMB
(p = 0.01). The NMP rate at RN was 2.7% (n = 1) with RMB and
9.0% without RMB (p = 0.20). Of note, the NMP RN
performed in the RMB group involved an RMB result
indicating unclassified RCC. The rate of emergency room
visits after biopsy was 2.5% and the readmission rate was
1.8%.
4.

Discussion

The MUSIC-KIDNEY initiative allows insight into the
current management of newly presenting T1 RMs across
the state of Michigan. Although the utility and efficacy
of RMB have been championed by several thought leaders
and institutions in Michigan [4,9,10], RMB utilization in
our cohort was limited at 15.5%, with wide variability
across MUSIC practices. In the context of prior rates
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Fig. 2 – Treatment rates for patients with a cT1 renal mass evaluated with or without renal mass biopsy and according to biopsy histology result.

reported in multiple academic series [11,12] and systematic reviews [2,13,14], this rate may appear to be
surprisingly low. Previous analysis of the National Cancer
Data Base (NCDB) and Surveillance, Epidemiology and
End Results (SEER) database reported RMB utilization
rates of 15.3–30.1% [15,16]. However, a major limitation of
the NCDB reporting is that it only includes patients with
known malignancy. In addition, the published data from
2015 focused on T1a RMs alone. The SEER data set also has
inherent issues regarding the study population, such as
inclusion of only those aged >66 yr, elimination of
negative RMB results, and exclusion of patients with
private insurance. Similarly, a study on RMB in the
Clinical Research Office of the Endourological Society
(CROES) renal mass registry reported incidence of 11.8%,
but investigated only T1a RMs [17]. Our study is the only
multicenter report to date that includes all T1 renal
masses (up to 7 cm) and is not limited by the inclusion of
only malignant histology. Our study is also unique in that
the collaborative includes diverse academic and private
groups, giving a “real world” look at RMB utilization.
Although RMB rates were higher in academic practices,
this was not a predictor of utilization on multivariate
regression, in contrast to previously published data [5].
The only patient factor associated with RMB use was
greater comorbidity, which has previously been reported
[16]. Age and renal function appeared to have no impact on
RMB rates in MUSIC-KIDNEY. One might expect that older
patients and those with lower renal function would be
more likely to undergo RMB since they are less likely to
proceed straight to intervention. Our findings do not
support this assumption and might be attributable to the
high rate of initial observation in our cohort of almost 50%
[8], which is frequently offered to such patients without
up-front RMB [28]. The high rate of observation is an
important feature of the treatment pattern for cT1 RM
within MUSIC-KIDNEY, with predictors of noninterventional management including lesion type (Bosniak III–
IV > solid; p = 0.017), tumor stage (T1a vs T1b; p < 0.001),
and higher age (p < 0.001) [28].

With regard to the decision to perform RMB, tumor size
played a role, as tumors of <1 cm were seldom managed
with RMB, while tumors of 1.1–7.0 cm in size had similar
rates of RMB utilization. This is intriguing considering the
significant literature regarding the use of RMB for SRMs, but
not for larger, localized suspected RCCs. The low rates of
biopsy for lesions of <1.0 cm in size is probably because
these lesions pose almost negligible metastatic potential
[18], are benign in almost 50% of cases on surgical removal
[19], and pose a greater technical challenge for RMB. In
MUSIC-KIDNEY, 77% of 0.1–1.0-cm cT1 RMs are managed
with observation, even without RMB [8]. Interestingly, RMB
was carried out for 16.3% of T1b lesions, of which 12.5% were
benign, which is similar to previously reported data at
surgery [19]. We suggest that the T1b population might be
the most suitable for RMB, as these patients have the most
to gain (or lose) with diagnosis of nonmalignant pathology.
RN was performed for almost 40% of T1b lesions in our
cohort. It has been shown that RN is associated with lower
non-RCC survival [20] and lower eGFR is strongly associated
with risk of death, cardiovascular events, and hospitalization [21]. It is therefore important to reduce unnecessary
decreases in renal function. In addition, although prior
studies observed associations of race and gender with RMB
utilization [16], we did not observe such an association.
We recently published the MUSIC-KIDNEY experience
with cT1 RMs to identify potential improvement opportunities to reduce overtreatment, including nephrectomy
[22]. Our data showed that 11% of cT1 RMs treated with
surgery had NMP, which is a lower rate than in most
published reports. Moderate to major quality improvement
opportunities were identified in nearly half of these cases,
most notably cases with the unintended outcome of RN for
NMP. NMP rates can be reduced by ensuring that dedicated
imaging is performed before any decision on surgery,
considering observational strategies, when appropriate, and
RMB. Our previous publication suggests a potential role for
RMB in reducing unnecessary treatment for NMP cases,
especially for patients for whom RN is planned or likely on
the basis of tumor complexity or size.
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As might be expected, patients in our study with cystic
tumors and anterior tumors were less likely to undergo RMB.
Other reports have shown lower diagnostic rates for cystic
RMs (83.6% vs 99.1%) [2,23] and there is controversy regarding
the appropriateness of RMB for cystic tumors given the
inherent challenges of adequate tumor sampling and some
concerns regarding tumor spillage [24–26]. RMB might be less
likely for anterior tumors because of closer proximity to the
bowel and visceral organs and a perceived risk of injury. No
difference in RMB rates by polar location was observed despite
presumed higher risks associated with upper-pole tumor
biopsy. Tumor complexity was not associated with RMB
utilization (although data were unavailable for just under half
of the patients). Although it has been shown that nephrometry
scoring can predict surgical complications and renal function
decline [27], no evidence is currently available on defining
suitability for RMB.
Our finding of sensitivity of 98.1% for RMB is similar to
that reported in a prior meta-analysis [2]. Specificity is,
however, lower than in prior reports, perhaps impacted by
the 95% of patients with a benign biopsy who underwent
surveillance with no surgical pathology for correlation.
Overall, the benign, malignant, and nondiagnostic rates
were similar to those previously reported [2,14].
RMB was associated with a significantly higher rate of
benign pathology at intervention, with no patients with a
benign RMB undergoing nephrectomy and almost all of
these patients opting for observation. Patients with a
malignant RMB were less frequently assigned to observation, in contrast to a prior report [15]. It is frequently argued
by opponents that RMB rarely changes management, but
our findings indicate that inclusion of RMB in an assessment
algorithm could avoid unnecessary intervention and better
select patients for treatment.
The study limitations include limited follow-up and
inclusion of practices with low numbers of RMBs. If
treatment occurred beyond the follow-up period, patients
could have been misclassified to observation. With ongoing
collection of data within the MUSIC-KIDNEY registry, there
will be opportunities to further assess RMB utilization and
patient outcomes. Our statewide quality improvement
database does not contain granular data to determine
indications for RMB, patient preferences during this period,
and how RMB ultimately affected decision-making. However, we did find that patient comorbidities and tumor
factors were associated with a higher rate of RMB, and these
factors were probably an important part of the shared
decision-making process on whether to perform RMB. In
addition, data for nephrometry scores and tumor position,
which could be useful in determining suitability for RMB,
were unavailable for up to half of the patients. Collecting
and recording tumor nephrometry data has been one
quality improvement goal for our collaborative.
5.

Conclusions

comorbidity and solid lesion type. The results for RMB
performed before treatment greatly impact management,
particularly when a benign histological diagnosis was made.
More widespread use of RMB could further reduce the
number of radical nephrectomies with findings of only
benign pathology.
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